Posted on 6/3/20
Johnson & Johnson: Built To Last
SummaryJohnson & Johnson is built to last with diverse revenue streams and strong competitive advantages in many of its markets.It has performed well both during the . . .
Posted on 5/11/20
Altria's Second Biggest Mistake: Cronos Continues To Wither
SummaryAltria invested $1.8 billion in Cronos. That investment has not paid off so far.Cronos has spent one-quarter of the funds from Altria, including purchasing a CBD . . .
Posted on 12/9/18
Altria And Cronos Tie The Knot: Did Altria Pay Too Much?
Altria purchases a potentially-majority stake in Cronos for C$2.4 billion.This is a great deal for Cronos shareholders, who will not benefit from the expertise of Altria . . .
Philadelphia
